1) Cappa M, E.Bertini, P.del Balzo, P.Cambiaso, A.Di Biase, S.Salvati. High dosage immunoglobulin I.V. treatment in adrenoleukodystrophy. Journal of Neurology, Neurosurgery and Psychiatry. 69-70,1994.
2) A.Di Biase, S.Salvati, T.Quaresima, F.Pieroni, A.Grisolia, P.Cambiaso, and M.Cappa. C24:0/C22:0 ratio in plasma sphingomyelinas a practical tool for the diagnosis of adrenoleukodystrophy and adrenomyeloneuropathy. ClinChemEnzymComms 7:35-40 1995.
3) Restuccia D. Di Lazzaro V, Valeriani M, OlivieroA, La Pera D, Barba C, Cappa M, Bertini E, e Tonali P. Abnormalities of somatosensory and motorevokedpotentials in adrenomyeloneuropathy. Muscle&Nerve 10: 1249-1257, 1997
4) Restuccia D, Di Lazzaro, Valeriani M, Oliviero A, La Pera D, Colosimo C, Burdi N, Cappa M, Bertini E, Di Biase A and Tonali P. Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degree of central nervous system involvment. Brain 120 :1139-1148, 1997.
5) A.DiBiase, S.Salvati, C.Avellino, M.Cappa, E.Bertini, L.Moroni, M.Rimoldi, G.Uziel. X-linked adrenoleukodystrophy: first report of the italian study group. Ital J NeurolSci 19: 315-319, 1998.
6) E.Shapiro, W.Krivit, L.Lockman, I.Jambaquè, C.Peters, M.Cowan, R.Harris, S.Blanche, P.Bordigoni, D.Loes, R.Ziegler, M. Crittende,. D.Ris, B.Berg, C.Cox, H.W.Moser, A.Fisher, P.Aubourg. Long-term effect of bone-marrow transplantation for childhood onset cerebral X-linked adrenoleukodystrophy. The lancet 356: 713-718, 2000,
7) Lira MG, Mottes M, Pignatti PF, Medica I, Uziel G, Cappa M, Bertini E, Rizzuto N, Salviati A. Detection of mutations in the ADRENOLEUCODISTROFIA gene (ABCD1) in seven italian families: description of four novel mutations. Hum Mutat 16 (3): 271, 2000
8) H.W. Moser, K.D. Smith P.A. Watkins, J Powers, A.B.Moser. X-linked adrenoleukodystrophy. In: Scriver CR Beadet AL Sly WS, Valle D eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill 2000: 3257-3301.
9) Di Biase A, Merendino N, Avellino C, Cappa M, Salvati S. Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy. Journal of the Neurological Sciences 1; 182(2):161-5 2001
10) F.S. Eicher, P.B.Barker, C.Cox, D.Edwin, A.M. Ulug, H.W. Moser and G.V. Raymond. Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 58: 901-907, 2002
11) A.S.Paintlia, A.G. Gilg, M.Khan, A.K.Singh, E.Barbosa and I.Singh. Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ADRENOLEUCODISTROFIA implications for potential therapies. Neurobiology of Disease, 14: 425-439, 2003
12) D.J.Loes, A.Fatemi, E.R.Melhem, N. Gupte, L.Bezman, H.W.Moser, G.V. Raymond. Analysis of MRI patterns aids prediction of progression in X-Linked adrenoleukodystrophy. Neurology 61:369-374, 2003
13) E.Mayatepek, M.BaumannT.Meissner, F.Hanefeld, G.C.Korenke. Role of leukotrienes as indicator of inflammatory demielinating reaction in X-linked cerebral adrenoleukodystrphy. J Neurol 2450: 1259-1260. 2003
14) Antioxidants Halt Axonal Degenerationin a Mouse Model of X-Adrenoleukodystrophy. Jone Lopez-Erauskin, Stephane Fourcade, Jorge Galino, Montserrat Ruiz, Agatha Schluter, Alba Naudi, Mariona Jove, Manuel Portero-Otin, Reinald Pamplona, IsidreFerrer, and Aurora Pujol. Ann Neurol. 2011 Jul;70(1)
